dMeetings online diabetes self-management education curriculum offers a new way to educate patients: five hours of DSME content developed and delivered by Certified Diabetes Educators (CDEs) and focused on positive patient outcomes reduces health care costs and increases patient and employee productivity.

The DPP-IV inhibitor sitagliptin was safe and effective over 3 years for adults aged at least 75 years who had well-controlled type 2 diabetes and cardiovascular disease, findings from an analysis of TECOS study data show.

We know from previous studies that obesity and type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease.

A DPP-4 inhibitor can help to prevent kidney function and did not have any negative cardiovascular effects.

Given the potential for CVD risk reduction associated with metformin and B-QR therapy individually, the present study explored the effect of add-on B-QR vs placebo to metformin on CVD outcomes in T2DM subjects.

Which of these Diabetes in Control features are you most likely to read/use? 1. Exclusive interviews 2. Textbook excerpts 3. New products 4. New mobile apps 5. Clinical presentations 6. I read/use them all Follow the link to share your response!

2016 in SGLT-2 Inhibitors: saw a host of important information on SGLT-2 inhibitors. Catch up with our best of 2016 articles.

What types of Diabetes in Control content do you find most valuable? 1. Information about new studies and treatments 2. Expert opinions/insights (interviews or guest articles) 3. News from conferences (ADA, AACE, etc.) 4. Case studies/personal accounts (for example, Disasters Averted) 5. Other Follow the link to share your response.

The US Food and Drug Administration (FDA) has approved empagliflozin (Jardiance, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly) for the new indication of improving survival in adults with type 2 diabetes and cardiovascular disease (CVD).

2016 could be remembered for the year when the diabetes class of drugs known as the SGLT-2 inhibitors has made a huge impact on the lives of those with type 2 diabetes today and into the future. Never in the history of the treatment for diabetes have we seen a new drug entry that reduce the risk for dying for those with diabetes.